Analysts Set Expectations for Adamas Pharmaceuticals Inc’s Q1 2021 Earnings (NASDAQ:ADMS)

Adamas Pharmaceuticals Inc (NASDAQ:ADMS) – Equities researchers at Piper Jaffray Companies issued their Q1 2021 earnings per share estimates for Adamas Pharmaceuticals in a research report issued on Thursday, November 7th, according to Zacks Investment Research. Piper Jaffray Companies analyst D. Amsellem anticipates that the specialty pharmaceutical company will post earnings of ($0.54) per share for the quarter. Piper Jaffray Companies also issued estimates for Adamas Pharmaceuticals’ Q2 2021 earnings at ($0.48) EPS, Q3 2021 earnings at ($0.44) EPS and FY2023 earnings at $0.65 EPS.

Adamas Pharmaceuticals (NASDAQ:ADMS) last posted its earnings results on Thursday, November 7th. The specialty pharmaceutical company reported ($0.99) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.90) by ($0.09). Adamas Pharmaceuticals had a negative return on equity of 205.30% and a negative net margin of 215.09%. The firm had revenue of $13.93 million for the quarter, compared to analyst estimates of $14.36 million.

ADMS has been the topic of a number of other research reports. Needham & Company LLC restated a “hold” rating on shares of Adamas Pharmaceuticals in a research report on Friday, November 8th. JMP Securities decreased their price target on Adamas Pharmaceuticals to $16.00 and set an “outperform” rating on the stock in a research report on Friday, November 8th. HC Wainwright restated a “buy” rating and issued a $30.00 price target on shares of Adamas Pharmaceuticals in a research report on Monday. Cowen set a $5.00 target price on Adamas Pharmaceuticals and gave the company a “hold” rating in a research report on Friday, August 9th. Finally, Northland Securities reiterated a “buy” rating and issued a $15.00 target price on shares of Adamas Pharmaceuticals in a research report on Friday, November 8th. Three investment analysts have rated the stock with a sell rating, five have given a hold rating and five have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $16.73.

Shares of NASDAQ ADMS traded down $0.11 during mid-day trading on Monday, reaching $6.40. The company had a trading volume of 616,484 shares, compared to its average volume of 485,044. The company has a debt-to-equity ratio of 6.72, a quick ratio of 6.15 and a current ratio of 6.35. Adamas Pharmaceuticals has a one year low of $3.35 and a one year high of $12.57. The firm has a market cap of $174.25 million, a price-to-earnings ratio of -1.31 and a beta of 1.77. The business’s 50-day simple moving average is $4.85 and its 200 day simple moving average is $5.47.

Institutional investors have recently added to or reduced their stakes in the business. Quantamental Technologies LLC bought a new position in Adamas Pharmaceuticals in the second quarter valued at about $25,000. Public Employees Retirement System of Ohio bought a new position in Adamas Pharmaceuticals in the third quarter valued at about $56,000. Dowling & Yahnke LLC acquired a new stake in shares of Adamas Pharmaceuticals during the third quarter valued at about $66,000. Advisor Group Inc. boosted its stake in shares of Adamas Pharmaceuticals by 53.4% during the second quarter. Advisor Group Inc. now owns 11,200 shares of the specialty pharmaceutical company’s stock valued at $69,000 after purchasing an additional 3,900 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale boosted its stake in shares of Adamas Pharmaceuticals by 63.8% during the second quarter. DekaBank Deutsche Girozentrale now owns 15,400 shares of the specialty pharmaceutical company’s stock valued at $91,000 after purchasing an additional 6,000 shares in the last quarter. Hedge funds and other institutional investors own 51.99% of the company’s stock.

About Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.

Featured Article: What is the Gross Domestic Product (GDP)?

Get a free copy of the Zacks research report on Adamas Pharmaceuticals (ADMS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.